Lexaria Bioscience Corp.
LEXX
$0.58
-$0.10-14.96%
NASDAQ
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.90M | -11.39M | -9.38M | -7.32M | -5.80M |
| Total Depreciation and Amortization | 115.80K | 112.00K | 95.80K | 109.10K | 108.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.14M | 885.60K | 791.90K | 634.40K | 621.00K |
| Change in Net Operating Assets | 195.60K | 693.60K | 1.11M | 72.80K | 106.50K |
| Cash from Operations | -10.45M | -9.70M | -7.38M | -6.50M | -4.96M |
| Capital Expenditure | -24.60K | -67.60K | -67.60K | -67.60K | -43.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -218.40K | -87.10K | -89.70K | -118.80K | -145.60K |
| Cash from Investing | -243.00K | -154.70K | -157.30K | -186.40K | -188.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.05M | 6.05M | 9.40M | 12.84M | 10.32M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.05M | 6.05M | 9.40M | 12.84M | 10.32M |
| Foreign Exchange rate Adjustments | -50.60K | -59.20K | -97.60K | -27.30K | -19.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.70M | -3.87M | 1.76M | 6.12M | 5.15M |